We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Epistem | LSE:EHP | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 85.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/5/2014 07:16 | Some interesting shareholders | the ghost who walks | |
27/4/2014 18:29 | This share has been a bit like the days of new GOLD mines , the Goldrush and shares in same Exciting to start with But it was the sellers of the picks, shovels and mining equipment and services to same that made the money and stayed the course as 99% of the mines went bust Fact 9 out of 10 small cap pharmas NEVER make it to profitability Costs of clinical studies run into $ many millions Roughly 1 in 1,000 new drug compounds makes it from pre-clinical stage to production Forbes research has just put the cost for a BIG Pharma developing a new drug at $ 5 BILLION Even they are now joining with each other cos they can't afford that kind of dough | buywell2 | |
27/4/2014 14:40 | In the results they said the following, wonder if we get an update:-- In April, we expect to enter the Indian regulatory approval process to complete our TB clinical studies, alongside commencing supplementary Nigerian TB studies in readiness for launch of our TB assay later in the year.-- Also in April, Genedrive(R) is expected to enter preliminary TB clinical studies in the US as a forerunner to a WHO recommendation in 2015. | the ghost who walks | |
22/4/2014 08:26 | Seems good news | the ghost who walks | |
09/4/2014 14:58 | Good announcement s | the ghost who walks | |
31/3/2014 14:00 | I sold out completey about 3 or 4 months ago but bought in again recently. I am dissapointed that the portfolio seems to keep shrinking unexpectedly. | azzi | |
29/3/2014 15:41 | Azzi why don't you sell then? | the ghost who walks | |
26/3/2014 05:57 | Of course gene drive potential is the reason to invest in this share. That's obvious. | the ghost who walks | |
25/3/2014 11:12 | Well I think all Epistems eggs are in one basket now, this is a much higher risk play than the co. I invested in 5 years ago. Genedrive quite simply HAS to deliver in a massive way! Will be watching very, very closely - no further delay will be acceptable to investors. | azzi | |
25/3/2014 07:47 | Agreed--------nevert | asph | |
25/3/2014 07:18 | Nice statement I think | the ghost who walks | |
22/2/2014 13:08 | Thanks Ghost. It would be nice to have a progress update however. | azzi | |
22/2/2014 11:18 | Results said 2nd half 2014 launch | the ghost who walks | |
16/2/2014 21:04 | Am I correct in my understanding that Genedrive will be launched with a 'Tb assay' during Q2 this year. We desperately need this. And I use the term "we" as I re-invested a smallish amount last week, this was based solely on the Genedrive launch.Let's hope this progresses as the CEO proclaimed. Any delay would not be tolerated by the market...or me! | azzi | |
30/1/2014 18:14 | Needs breakthrough ---- they have potential to produce something explosive in medicine | asph | |
30/1/2014 17:33 | Looks good mgt hires | the ghost who walks | |
29/12/2013 19:41 | Hmmm.. I remain perplexed. The recent announcement re- US military evaluation and FIND initiative should have given an upward push for the share price It seems the Genedrive system is now the key focus of attention for EPH, what has happened to all the other ground backing technologies? The launch of the first genedrive test had better not be delayed - I still feel we are not aware of the full picture here, is the genedrive system really that good? BD walked away from it , right or wrong? I am a confused long term ex-investor, however I would consider re-investing if I believe the story. | azzi | |
22/12/2013 11:20 | Seems promising agm statement | the ghost who walks | |
07/12/2013 15:53 | Director buy | the ghost who walks | |
24/11/2013 20:59 | Still watching, but without any sort of official update from the company I am still scratching my head as to what has /is going so wrong. All I can assume is that the facts may not match the hype. Well this is AIM! | azzi | |
19/11/2013 08:16 | Can but agree Azzi----------very disappointed with EHP | asph | |
10/11/2013 20:12 | Hmmm....I sense something has significantly changed within Epistem - I can't put my finger on it but after 30 years of investing I am not comfortable to re-invest having completely selling out recently. I sense the company are not being quite as transparent as I had believed... We now seem to be focusing on Genedrive - yet BD appears to have walked away from this recently - hence the demise of the share price I didn't realise that this project was of such high priority. Epistem need to re-assure me that they are in control and can launch gendrive on time - because I can't escape the nagging question - WHY did BD walk? I can't quite work this out unless BD knew of something not in the public domain yet. Watching closely. | azzi | |
28/10/2013 15:43 | Agreed looks very nasty - Big gap down to some 180 - 200p. Did anyone still holding invest through Beer & Co before it floated ? | pugugly |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions